Total
0
Shares
Holista CollTech (ASX:HCT) - CEO, Dr Rajen Manicka - The Market Herald
CEO, Dr Rajen Manicka
Sourced: Valentus
  • Holista CollTech (HCT) has begun testing Path-Away at a microbiology laboratory in the U.K.
  • This testing will be completed in collaboration with Global Infections Control Consultants
  • These tests will determine Path-Away's efficacy as a sanitiser against Covid-19
  • Path-Away cripples a virus' cell walls, causing bacteria to group together and destroy themselves within seconds
  • Testing is expecting to be completed by mid-April and results are expected 2-3 weeks after that
  • Holista's share price remains flat and shares are currently trading for 9.4 cents each

On March 12, Holista CollTech (HCT) began testing Path-Away at a microbiology laboratory in the United Kingdom.

This testing will be completed in collaboration with Global Infections Control Consultants LLC (GICC LLC).

These tests will determine Path-Away's efficacy as a sanitiser against Covid-19. The tests are expected to be completed before the end of next month.

Testing will also be completed on other members of the coronavirus branch such as SARS (severe acute respiratory syndrome) and the more common human influenza virus.

"Since the start of the year we have accorded testing against Covid-19 as a top priority," CEO Dr Rajen Manicka said.

"However, the situation in China until recent days has led to delays in obtaining samples of the coronavirus and there was the issue of high security around the testing facilities. As such, we are really pleased testing has commenced in a globally recognised laboratory," he added.

Path-Away is used in Holista's NatShield sanitising spray which is known to kill more than 170 bacteria, viruses and fungi.

It is a plant-derived antimicrobial compound which cripples a virus' cell walls, causing bacteria to group together and destroy themselves within seconds.

Results for the study are expected within 2-3 weeks of the completion.

Holista's share price remains flat and shares are trading for 9.4 cents each at 1:02 pm AEDT.


Subscribe


HCT by the numbers
More From The Market Herald
PainChek (ASX:PCK) - CEO, Philip Daffas - The Market Herald

" No pain for PainChek (ASX:PCK) over December quarter

PainChek (PCK) had a period of continued growth in the December quarter, particularly in the aged care sector.
MyFiziq (ASX:MYQ) - CEO, Vlado Bosanac - The Market Herald

" MyFiziq (ASX:MYQ) agrees to loan Bearn A$645K

Body scanning specialist MyFiziq (MYQ) has entered a new funding agreement with U.S. app creator Bearn.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep’s (ASX:IMM) ulcerative colitis study discontinued

Biotechnology company Immutep (IMM) has been advised that its phase two clinical trial on ulcerative colitis has been discontinued.
Botanix Pharmaceuticals (ASX:BOT) - President, Vince Ippolito - The Market Herald

" Botanix Pharmaceuticals (ASX:BOT) rounds off December quarter with $19.2M in cash

After a successful December quarter, Botanix Pharmaceuticals (BOT) rounded it off with $19.2 million in cash.